IGC Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -953.4% compared to IGC Pharma, Inc.'s net margin of --. IGC Pharma, Inc.'s return on equity of -94.42% beat CEL-SCI Corp.'s return on equity of -266.61%.

IGC Pharma, Inc. has a consensus price target of $3.75, signalling upside risk potential of 1141.72%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 613.09%. Given that IGC Pharma, Inc. has higher upside potential than CEL-SCI Corp., analysts believe IGC Pharma, Inc. is more attractive than CEL-SCI Corp..

IGC Pharma, Inc. has a beta of 0.242, which suggesting that the stock is 75.839% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

IGC Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

IGC Pharma, Inc. quarterly revenues are $191K, which are larger than CEL-SCI Corp. quarterly revenues of --. IGC Pharma, Inc.'s net income of -$1.8M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, IGC Pharma, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma, Inc. is 22.66x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Esperion Therapeutics, Inc. has a net margin of -953.4% compared to IGC Pharma, Inc.'s net margin of -35.89%. IGC Pharma, Inc.'s return on equity of -94.42% beat Esperion Therapeutics, Inc.'s return on equity of --.

IGC Pharma, Inc. has a consensus price target of $3.75, signalling upside risk potential of 1141.72%. On the other hand Esperion Therapeutics, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 72.02%. Given that IGC Pharma, Inc. has higher upside potential than Esperion Therapeutics, Inc., analysts believe IGC Pharma, Inc. is more attractive than Esperion Therapeutics, Inc..

IGC Pharma, Inc. has a beta of 0.242, which suggesting that the stock is 75.839% less volatile than S&P 500. In comparison Esperion Therapeutics, Inc. has a beta of 1.009, suggesting its more volatile than the S&P 500 by 0.85%.

IGC Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Esperion Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma, Inc. pays -- of its earnings as a dividend. Esperion Therapeutics, Inc. pays out -- of its earnings as a dividend.

IGC Pharma, Inc. quarterly revenues are $191K, which are smaller than Esperion Therapeutics, Inc. quarterly revenues of $87.3M. IGC Pharma, Inc.'s net income of -$1.8M is higher than Esperion Therapeutics, Inc.'s net income of -$31.3M. Notably, IGC Pharma, Inc.'s price-to-earnings ratio is -- while Esperion Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma, Inc. is 22.66x versus 2.46x for Esperion Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NRX Pharmaceuticals, Inc. has a net margin of -953.4% compared to IGC Pharma, Inc.'s net margin of -2433.88%. IGC Pharma, Inc.'s return on equity of -94.42% beat NRX Pharmaceuticals, Inc.'s return on equity of --.

IGC Pharma, Inc. has a consensus price target of $3.75, signalling upside risk potential of 1141.72%. On the other hand NRX Pharmaceuticals, Inc. has an analysts' consensus of $36.50 which suggests that it could grow by 1414.52%. Given that NRX Pharmaceuticals, Inc. has higher upside potential than IGC Pharma, Inc., analysts believe NRX Pharmaceuticals, Inc. is more attractive than IGC Pharma, Inc..

IGC Pharma, Inc. has a beta of 0.242, which suggesting that the stock is 75.839% less volatile than S&P 500. In comparison NRX Pharmaceuticals, Inc. has a beta of 1.914, suggesting its more volatile than the S&P 500 by 91.412%.

IGC Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NRX Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma, Inc. pays -- of its earnings as a dividend. NRX Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

IGC Pharma, Inc. quarterly revenues are $191K, which are smaller than NRX Pharmaceuticals, Inc. quarterly revenues of $242K. IGC Pharma, Inc.'s net income of -$1.8M is higher than NRX Pharmaceuticals, Inc.'s net income of -$5.9M. Notably, IGC Pharma, Inc.'s price-to-earnings ratio is -- while NRX Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma, Inc. is 22.66x versus 170.09x for NRX Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theravance Biopharma, Inc. has a net margin of -953.4% compared to IGC Pharma, Inc.'s net margin of 18.08%. IGC Pharma, Inc.'s return on equity of -94.42% beat Theravance Biopharma, Inc.'s return on equity of 14.9%.

IGC Pharma, Inc. has a consensus price target of $3.75, signalling upside risk potential of 1141.72%. On the other hand Theravance Biopharma, Inc. has an analysts' consensus of $26.71 which suggests that it could grow by 41.42%. Given that IGC Pharma, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe IGC Pharma, Inc. is more attractive than Theravance Biopharma, Inc..

IGC Pharma, Inc. has a beta of 0.242, which suggesting that the stock is 75.839% less volatile than S&P 500. In comparison Theravance Biopharma, Inc. has a beta of 0.143, suggesting its less volatile than the S&P 500 by 85.696%.

IGC Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theravance Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma, Inc. pays -- of its earnings as a dividend. Theravance Biopharma, Inc. pays out -- of its earnings as a dividend.

IGC Pharma, Inc. quarterly revenues are $191K, which are smaller than Theravance Biopharma, Inc. quarterly revenues of $20M. IGC Pharma, Inc.'s net income of -$1.8M is lower than Theravance Biopharma, Inc.'s net income of $3.6M. Notably, IGC Pharma, Inc.'s price-to-earnings ratio is -- while Theravance Biopharma, Inc.'s PE ratio is 33.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma, Inc. is 22.66x versus 11.86x for Theravance Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.